ADVANCED MELANOMA
Clinical trials for ADVANCED MELANOMA explained in plain language.
Never miss a new study
Get alerted when new ADVANCED MELANOMA trials appear
Sign up with your email to follow new studies for ADVANCED MELANOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo shows promise for Tough-to-Treat melanoma
Disease control CompletedThis early-phase study tested a combination of two drugs, trametinib and ceritinib, in 27 people with advanced melanoma that had not responded to previous treatments. The main goal was to find the safest dose and see if the combination could shrink tumors. While not a cure, the a…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 26, 2026 09:27 UTC
-
New drug combo shows promise in advanced skin cancer trial
Disease control CompletedThis early-phase study tested a new drug called LBL-007 combined with two other medications (toripalimab and axitinib) in 79 people with advanced melanoma that could not be removed by surgery or had spread. The main goals were to check safety and find the best dose. Researchers a…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1 • Sponsor: Nanjing Leads Biolabs Co.,Ltd • Aim: Disease control
Last updated May 26, 2026 08:19 UTC
-
Personalized vaccine plus immunotherapy shows promise against advanced melanoma
Disease control CompletedThis study tested whether adding a personalized cancer vaccine (RO7198457) to the immunotherapy drug pembrolizumab works better than pembrolizumab alone for people with advanced melanoma that hasn't been treated before. The trial included 131 participants with stage III or IV mel…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 22, 2026 14:02 UTC
-
New combo injection shows promise for Tough-to-Treat melanoma
Disease control CompletedThis study tested a new drug combination for people with advanced melanoma that no longer responds to standard immunotherapy. The treatment involves injecting LTX-315 directly into tumors along with pembrolizumab, an immunotherapy drug given through the vein. The goal was to see …
Matched conditions: ADVANCED MELANOMA
Phase: PHASE2 • Sponsor: Lytix Biopharma AS • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New combo therapy targets Hard-to-Treat cancers
Disease control CompletedThis early-stage trial tested a new drug called CyPep-1, injected directly into tumors, combined with the immunotherapy pembrolizumab. It included 6 adults with advanced head and neck cancer, melanoma, or triple-negative breast cancer that had spread. The goal was to see if the c…
Matched conditions: ADVANCED MELANOMA
Phase: PHASE1, PHASE2 • Sponsor: Cytovation AS • Aim: Disease control
Last updated May 19, 2026 12:01 UTC
-
Cancer moonshot study banks tumors to unlock genetic secrets
Knowledge-focused CompletedThis study collected blood and tumor tissue from 64 people with advanced or treatment-resistant cancers. Researchers stored these samples in a biobank and performed genetic tests to learn how genes influence cancer growth and response to therapy. The goal was to build a resource …
Matched conditions: ADVANCED MELANOMA
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated May 26, 2026 09:43 UTC
-
Blood tests may reveal who will respond to melanoma immunotherapy
Knowledge-focused CompletedThis study examined blood and tumor samples from 25 people with advanced melanoma to understand why some respond to the immunotherapy drug pembrolizumab while others do not. Researchers analyzed T cells—key immune cells—to find genetic and behavioral clues that predict treatment …
Matched conditions: ADVANCED MELANOMA
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated May 26, 2026 09:32 UTC